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Long-term valproate treatment is associated with polycystic ovaries and endocrine disorders in women with epilepsy. The
mechanisms responsible for these effects are unknown, but both the epilepsy itself and the drug per se may be of importance.
The aim of this study was to investigate possible effects of the drug on gonadal structure and function in animals with no
epileptic disorders. Three groups, each of 15 female Wistar rats, were fed perorally with a valproate mixture (50 mg/kg or
200 mg/kg) or control solution once daily for 90 days, giving mean valproate concentrations within the normal human range. A
significant, 20% increase in ovary weight was found in both low- (P = 0.027) and high- (P < 0.001) dose animals together with
a significantly increased number of ovarian follicular cysts. Mean serum testosterone concentration was significantly reduced in
both low- and high-dose animals. There was a non-significant trend towards reduced estrogen levels, while progesterone levels
were unchanged. Even if the hormonal changes are somewhat different from those in humans, the findings demonstrate that
changes in gonadal structure and endocrine function also occur in intact animals indicating a drug-specific effect. Our findings
encourages further studies using animal models to elucidate possible mechanisms involved in the endocrine side-effects of
antiepileptic drugs.
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Long-term valproate treatment is associated with poly-
cystic ovaries and endocrine disorders in women
with epilepsy1–4. This is of major clinical importance
with valproate being one of the most frequently used
antiepileptic drugs worldwide. The mechanisms re-
sponsible for the endocrine side-effects are, however,
still unknown. Some investigators have claimed that
the effects are due to the epilepsy itself 5, 6, while oth-
ers have claimed a drug-specific effect on endocrine
function1, 2, 7.
The aim of the present study was to investigate
whether polycystic ovaries could also be induced by1059–1311/99/080490 + 04 $12.00/0long-term valproate monotherapy in intact animals
thereby indicating a drug-specific effect. This study
also represents an attempt towards an animal model
for studying possible mechanisms involved in the de-
velopment of endocrine effects of antiepileptic drugs.
MATERIALS AND METHODS
Forty-five female Wistar rats were fed perorally
through a gastric tube with a valproate or control mix-
ture once daily for 90 days. All animals were at the age
of 80 days at the beginning of the study. The drug used
was a standard, commercially available valproate mix-c© 1999 BEA Trading Ltd
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Table 1: Ovarian morphological and endocrine changes after
long-term valproate treatment.
Morphological changes
Mean SD Range P
Ovary weight Control 51 7.5
(mg) VPA 50 mg/kg 65 9.9 < 0.001
VPA 200 mg/kg 59 6.3 0.027
No. of ovarian Control 0.50 0.76 0–2
follicular cysts VPA 50 mg/kg 0.86 0.95 0–3 0.69
VPA 200 mg/kg 1.27 0.59 0–2 0.034
No. of corpora Control 14.6 4.3 8–20
lutea VPA 50 mg/kg 14.8 3.5 9–19 NS
VPA 200 mg/kg 12.5 3.8 7–22 NS
No. of Control 11.1 3.0 5–16
follicles VPA 50 mg/kg 11.5 3.2 6–18 NS
VPA 200 mg/kg 11.7 4.9 5–22 NS
Endocrine changes
Testosterone Control 1.44 0.44
nmol/l VPA 50 mg/kg 0.96 0.40 0.029
VPA 200 mg/kg 0.90 0.56 0.011
Free testosterone Control 0.89 0.96
pmol/l VPA 50 mg/kg 0.72 1.07 NS
VPA 200 mg/kg 0.33 0.46 0.11
Estradiol Control 44.5 38.5
pmol/l VPA 50 mg/kg 31.6 36.2 0.35
VPA 200 mg/kg 28.9 29.9 0.36
Progesterone Control 46.0 32.7
nmol/l VPA 50 mg/kg 68.9 61.7 NS
VPA 200 mg/kg 54.1 54.1 NSture, with a control mixture without the drug, kindly
supplied by Desitin Pharma, Norway. The animals
were divided in three groups, each of 15 animals, re-
ceiving either valproate 50 mg/kg, 200 mg/kg or a
control solution. The animals were weighed at the first
study day and the doses were later adjusted for weight
gain every week.
After 90 days, the animals were sacrificed 4 hours
after their last dose of valproate. When sacrificed, all
animals were in late diestrus/early proestrus accord-
ing to vaginal smears. The blood was collected and
serum frozen at −20 ◦C until analysis. The ovaries
were weighed and thereafter immediately fixed in for-
malin. For microscopical evaluation of the ovaries,
three mid-ovarian sections were cut and the total num-
ber of cysts, follicles and corpora lutea were counted.
The mid-ovarian section with the highest number of
cysts, follicles or corpora lutea from each animal was
used for the statistical analysis.
Serum testosterone and progesterone concentra-
tions were measured by the Chiron Diagnostics
ACS:180 automated chemiluminescence system using
an ACS:180 analyser. Serum 17-beta-estradiol con-
centrations were analyzed by radioimmunoassay with
kits obtained from Orion Diagnostica (Turku, Finland)
after extraction of the serum samples with ether/ethyl
acetate (9:1). The concentrations of serum-free testos-
terone were measured by radioimmunoassay using
kits obtained from Diagnostic Products Corp. (Los
Angeles, CA). Serum valproate concentrations were
analyzed by a fluorescence polarization immunoassay
system using an AxSym analyzer (Abbott Diagnostic
Division, Irving, Tx).
The statistical analyses were performed with a one-
way ANOVA technique using a commercially avail-
able software package (SPSS). All significant ob-
servations were checked and confirmed with a non-
parametric Kruskall–Wallis test.
RESULTS
All animals tolerated the treatment and the gastric
tube feeding without any signs of discomfort or re-
duced motor activity. Two animals, one from the con-
trol and one from the low-dose group, died because of
esophageal rupture by the gastric tube with concom-
mittant intrathoracic bleeding, according to autopsy
findings. Mean valproate concentration when sacri-
ficed 4 hours after last dose was 72 µmol/l (n = 14)
in low-dose and 200 µmol/l (n = 15) in high-dose
animals. In the high-dose group, additional serum con-
centration measurements showed that the mean serum
level of valproate was 999 µmol/l (n = 3) 2 hours,
157 µmol/l (n = 1) 6 hours, and 3 µmol/l (n = 2)
24 hours after the last dose.A significant, about 20% higher ovary weight was
found in both low- and high-dose animals when com-
pared with the controls (Table 1). Mean total body
weight was unchanged with 251 g in controls and
258 g and 248 g in low- and high-dose groups, respec-
tively.The mean number of cysts per section increased
progressively and significantly with higher valproate
doses from 0.5 cysts/section in the control animals
to 0.86 and 1.27 in the low- and high-dose groups, re-
spectively (Table 1) (Fig. 1).
A significant reduction in serum testosterone con-
centration was observed with an approximately 40%
reduction in high-dose animals as compared with
the control animals (Table 1). A progressive, dose-
dependent reduction in free testosterone concentration
was also observed. Serum estradiol concentration was
markedly reduced by about 35% after high-dose val-
proate treatment. The free testosterone and estrogen
data did, however, not reach statistical significance.
This might be due to the low number of animals and
the large between-animal variability. Progesterone was
unchanged after valproate treatment. In addition, no
changes were observed in albumin concentrations.
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Fig. 1: (a), An ovary from a control rat demonstrating normal ovarian morphology (magnification x28, staining: Hematoxylin-Eosin,
rat no. 10); (b), an ovary from a high-dose valproate treated rat demonstrating enlarged follicular cysts (magnification x28, rat
no. 36).DISCUSSION
This is the first report to have been able to demonstrate
morphological changes in the ovaries and changes in
sex steroid hormones in animals after long-term val-
proate treatment. An increase in ovary weight and the
increased number of cystic formations in the ovaries of
intact, non-epileptic animals are in general agreement
with observations in humans of polycystic ovaries and
endocrine changes in women on valproate monother-
apy1–3. This implies that valproate treatment per se
leads to endocrine changes and alterations of ovarian
morphology independent of the species studied and
underlying epilepsy.
The endocrine changes in the animals seem, how-
ever, to differ from those previously observed in hu-
mans2 with a decrease rather than increase in testos-
terone. However, new observations in humans haveshown that polycystic ovaries are not always associ-
ated with hyperandrogenism in female patients8. Ear-
lier animal studies have also demonstrated testicular
atrophy in male rats and dogs, indicating reduced an-
drogen levels in agreement with our findings9, 10.
The valproate doses used in our study might seem
high when compared to human doses. However, our
maximum dose of 200 mg/kg/day was within the hu-
man therapeutic range on a mg/m2 basis. In accor-
dance with this, in our study the serum concentrations
measured 4 hours after the last dose were even be-
low the lower therapeutic range in humans. It might
be speculated that a high peak concentration of val-
proate after a single dose could be responsible for the
effects of the drug on the endocrine system. How-
ever, the drug was given perorally requiring normal
absorption time from the bowel. Also, the effects on
the ovaries in humans are observed after conventional
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Editore, 1998: pp. 49–53.peroral treatment. It is thus unlikely that abrupt fluctu-
ations in valproate concentrations in the rats are of any
major importance for the observed changes in ovarian
morphology and endocrine functions.
It is further unlikely that the effects observed are
due to other toxic effects of the drug in the animals.
There was no difference in weight gain or observed
motor activity between the different groups of animals
indicating normal thriving in the animals. One- and
three-month studies with valproate in Long-Evans rats
found a ‘no-toxic-effect’ dose of 270 mg/kg/day11.
In a six-month feeding study in Sprague–Dawley rats,
no toxicity was observed at dosages of valproate of
341 mg/kg/day in males and 416 mg/kg/day in fe-
males11. A light microscope examination of the liver,
heart, kidney, lung and brain of all our animals did not
show any abnormalities12. Thus, most likely, valproate
exerts a specific effect on ovarian morphology.
In conclusion, our study has shown that valproate
also induces endocrine changes and alterations in ovar-
ian morphology in an animal model. Although the
changes in hormone levels do not seem to be directly
applicable to humans, the results encourage further at-
tempts to study endocrine side-effects of antiepileptic
drugs.
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